FIL Ltd Acquires 140,608 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

FIL Ltd boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 737.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 159,671 shares of the company's stock after acquiring an additional 140,608 shares during the quarter. FIL Ltd owned 0.16% of Intellia Therapeutics worth $1,862,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of NTLA. Stifel Financial Corp grew its holdings in shares of Intellia Therapeutics by 3.4% in the third quarter. Stifel Financial Corp now owns 94,610 shares of the company's stock worth $1,944,000 after purchasing an additional 3,102 shares during the last quarter. State Street Corp increased its position in shares of Intellia Therapeutics by 17.9% in the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock valued at $105,700,000 after acquiring an additional 780,754 shares during the period. Barclays PLC raised its stake in shares of Intellia Therapeutics by 17.7% during the third quarter. Barclays PLC now owns 292,795 shares of the company's stock valued at $6,017,000 after acquiring an additional 44,022 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Intellia Therapeutics by 2.2% during the third quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company's stock worth $48,164,000 after purchasing an additional 49,367 shares during the period. Finally, Virtu Financial LLC purchased a new position in Intellia Therapeutics during the 3rd quarter valued at about $417,000. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Price Performance

NTLA stock traded up $0.37 during trading on Friday, hitting $7.23. 2,864,822 shares of the stock traded hands, compared to its average volume of 2,340,348. The stock has a market cap of $748.43 million, a price-to-earnings ratio of -1.33 and a beta of 2.23. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $28.18. The firm's 50 day moving average is $8.93 and its two-hundred day moving average is $12.28.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on NTLA shares. Morgan Stanley lowered Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Wells Fargo & Company reduced their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Citigroup increased their price target on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the stock a "neutral" rating in a research note on Friday, February 28th. The Goldman Sachs Group reaffirmed a "sell" rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. Finally, Wedbush reissued a "neutral" rating and issued a $10.00 target price (down previously from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $37.56.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.